# Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

> **NCT06026371** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 138 (estimated)

## Conditions studied

- Acute Graft Versus Host Disease
- Hematopoietic and Lymphatic System Neoplasm

## Interventions

- **DRUG:** Fecal Microbiota Transplantation Capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06026371
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-12
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-03-31
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06026371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06026371, "Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06026371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*